Most potential oncology drugs fail during the drug development pipeline, even when there has been promising data for their efficacy during the in vitro stage. This makes it vital to identify in vitro ...

Not all α-synuclein inclusions are created equal. That’s the upshot from a new stem cell approach to study “inclusionopathies,” such as Parkinson’s and Alzheimer’s diseases. As reported in the ...